Just in case it’s slipped suffering shareholders minds, and to...

Just in case it’s slipped suffering shareholders minds, and to put the 1k share purchase in 2022 into crystal clear perspective:

*** $2 million pay rise for Melbourne biotech boss ***

https://www.copyright link/policy/economy/2-million-pay-rise-for-melbourne-biotech-boss-20201112-p56e07

https://www.copyright link/policy/economy/2-million-pay-rise-for-melbourne-biotech-boss-20201112-p56e07

The boss of biotech Clinuvel Pharmaceuticals, Philippe Wolgen, pocketed a ***$2 million pay rise this year to make $3.4 million*** topping the list of the biggest chief executive officer pay rises*** despite giving up his $750,000 annual bonus,which the board lauded as "unusual and amazing" leadership.

The sizeable pay rise – in the midst of a global pandemic and economic recession – reflects a broader trend to emerge from The Australian Financial Review'sannual CEO pay surveythis year, which showed a changing of the guard from excessive pay in banking to biotechs and start-ups. CSL's CEO Paul Perreault topped the list of highest-paid CEOs, overtaking Macquarie's Shemara Wikramanayake.

The French-born Dr Wolgen, whose hobbies include running, skiing and piloting helicopters, heads thesmall Melbourne drug company that is breaking new ground in the treatment of skin disease and stroke. He holds a major stake in the company, worth more than $71 million.

As much as $44 million more in shares may also head his way under a share grant made last year. Wednesday's annual meeting triggered a "strike" and a 32.5 per cent protest vote, with a spray from chairman Willem Blijdorp at short-sellers.